Christy Dunbar
Family Medicine · Leesville, SCNPI 1366437907
Payments from drug & device makers
Across 331 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$827
- GSK$561
- Forte Bio-pharma LLC$540
- AbbVie$525
- Lilly USA, LLC$242
- Novo Nordisk$235
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,21099%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $827 |
| GSK | 43 | $561 |
| Forte Bio-pharma LLC | 31 | $540 |
| AbbVie | 51 | $525 |
| Lilly USA, LLC | 15 | $242 |
| Novo Nordisk | 16 | $235 |
| Bayer | 10 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $207 |
| Pfizer | 13 | $192 |
| Insulet Corporation | 8 | $188 |
| Boehringer Ingelheim | 10 | $186 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Exact Sciences | 7 | $124 |
| Otsuka America Pharmaceutical, Inc. | 6 | $111 |
| Hikma Pharmaceuticals USA | 6 | $110 |
| Biohaven Pharmaceuticals, Inc. | 6 | $100 |
| Amgen | 5 | $85 |
| Optinose US, Inc. | 4 | $82 |
| Abbott | 4 | $77 |
| Dexcom, Inc. | 2 | $64 |
| Merck | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Virtus Pharmaceuticals LLC | 3 | $41 |
| Novartis | 3 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Johnson & Johnson | 2 | $32 |
| Harmony Biosciences LLC | 1 | $29 |
| Corcept Therapeutics | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Stryker | 1 | $19 |
| Edwards Lifesciences | 1 | $17 |
| Corium, LLC | 1 | $16 |
| Indivior Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
How this compares
$5,252 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $104,263 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $59,907 |
| JardianceEmpagliflozin | 51 | $53,410 |
| JanuviaSitagliptin Phosphate | 32 | $33,571 |
| FarxigaDapagliflozin Propanediol | 29 | $32,794 |
| TrulicityDulaglutide | 25 | $31,792 |
| LinzessLinaclotide | 17 | $16,527 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $15,243 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $13,671 |
| EliquisApixaban | 12 | $10,934 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 15 | $9,803 |
| TradjentaLinagliptin | 12 | $7,134 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 63 | $6,198 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 195 | $5,702 |
| Novolog FlexpenInsulin Aspart | 25 | $4,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $235 | $104,26396 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $827 | $61,70890 claims |
| Boehringer IngelheimJardiance, Tradjenta | $186 | $60,54363 claims |
| GSKTrelegy Ellipta | $561 | $59,90755 claims |
| MerckJanuvia | $51 | $33,57132 claims |
| Lilly USA, LLCTrulicity | $242 | $31,79225 claims |
| AbbVieLinzess | $525 | $16,52717 claims |
| PfizerEliquis | $192 | $10,93412 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $110 | $7,21495 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Leesville
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.